Molecule intelOpportunity: Lower0Crowded market

Orphenadrine

105 brands · 76 companies · product forms

1 DRAP alert

Opportunity snapshot

Launch attractiveness
26
Market saturation
91
Price room
100
Regulatory risk
40
105
brands
76
companies
Rs 296.05
median price
23
price points
23.82x
price spread
90
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 6%

Price room

Across observed sources and strengths
CheapestRs 35.68
MedianRs 296.05
Most expensiveRs 849.8
Spread23.82×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 23.82x across 23 trusted points (Rs 35.68-849.8). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Orphenadrine — each links to its own medicine page.

Regulatory alerts

latest 2023-04-13
Drug Safety Alert: Risk of complex sleep behaviours with Zolpidem

Why this score

Launch attractiveness

40% supply-gap(0) + 25% price-variation(100) + 20% low-competition(9) + 15% supply-disruption(0), damped by confidence(90). Higher = more attractive, less crowded opportunity.

Market saturation

76 canonical companies and 105 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 23.82x across 23 trusted points (Rs 35.68-849.8). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

1 DRAP alert(s), latest 2023-04-13.

Confidence

Reduced by: no ATC code.

Packaged brief for this lower opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.